Seeing Is Believing

Currently out of the existing stock ratings of Mark Breidenbach, 180 are a BUY (97.3%), 5 are a HOLD (2.7%).
Analyst Mark Breidenbach, carries an average stock price target met ratio of 35.44% that have a potential upside of 48.94% achieved within 203 days. Previously, Mark Breidenbach worked at OPPENHEIMER, ROTH MKM, HC WAINWRIGHT.
Mark Breidenbach’s has documented 343 price targets and ratings displayed on 30 stocks. The coverage was on Healthcare, Industrials, Technology, Consumer Cyclical sectors.
Most recent stock forecast was given on BLUE, Bluebird bio at 15-Aug-2024.
Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) at 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%) receiving and performance score of 46.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Aug-2026
$6
$4.75 (380.00%)
$5
2 months 13 days ago
(17-Aug-2026)
1/10 (10%)
$3.92 (188.46%)
148
Buy Since 15-Apr-2026
$10
$8.5 (566.67%)
$10
6 months 8 days ago
(22-Apr-2026)
0/2 (0%)
$7.61 (318.41%)
Buy Since 04-Apr-2023
$11
$8.87 (416.43%)
$12
6 months 14 days ago
(16-Apr-2026)
0/12 (0%)
$8.63 (364.14%)
Sell Since 16-Apr-2026
6 months 14 days ago
(16-Apr-2026)
0/3 (0%)
$2.86 (55.64%)
Hold Since 21-Mar-2023
$3.85
$1.72 (80.75%)
$2.5
6 months 16 days ago
(14-Apr-2026)
2/3 (66.67%)
$1.13 (41.54%)
155